Quattrone Filippo, Canale Alice, Filippetti Elisa, Tulipani Alberto, Porretta Andrea, Lopalco Pier L
Unit of Hygiene and Epidemiology, Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy -
Unit of Hygiene and Epidemiology, Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Minerva Pediatr. 2018 Feb;70(1):59-66. doi: 10.23736/S0026-4946.17.05147-7.
To date three vaccines against human papilloma virus (HPV) have been licensed: a bivalent, a quadrivalent and, in 2014, a nonavalent vaccine. Despite the early implementation of national vaccination programs, in the majority of developed countries coverage rates remain unsatisfactory. Rumors about vaccine safety have been one of the principal obstacles for the acceptance of HPV vaccination by the public. It is therefore of primary importance to provide the public with clear and up-to-date information about HPV vaccination safety. To this aim, in this narrative review we will summarize safety data from pre and postlicensure studies for the three HPV vaccines available with a focus on the safety profile of the new nonavalent vaccine.
迄今为止，三种针对人乳头瘤病毒（HPV）的疫苗已获许可：一种二价疫苗、一种四价疫苗，以及在2014年获批的一种九价疫苗。尽管各国早期就实施了国家疫苗接种计划，但在大多数发达国家，疫苗接种覆盖率仍不尽人意。关于疫苗安全性的谣言一直是公众接受HPV疫苗接种的主要障碍之一。因此，向公众提供有关HPV疫苗接种安全性的清晰且最新的信息至关重要。为此，在本叙述性综述中，我们将总结三种现有HPV疫苗在获批前和获批后的研究中的安全性数据，重点关注新型九价疫苗的安全性概况。
